He Jie Tang in the treatment of chronic hepatitis B patients

Table 3 Serum levels of TNF-α, sIL-2R, and IL-8 as well as NK activity before and after the treatment (mean±SD)

		n	TNF-a (mg/L)	sIL-2R (kU/L)	IL-8 (μg/L)	NK (%)
Group III		20	0.58±0.23	310.0±30.7	0.72±0.2	59.65±7.5
Group I	Pre-T	50	18.8±8.9b	390.9±12.0b	2.42±0.8b	43.12±6.5b
	Post-T	50	10.5±6.8a	310.22±8.9a	1.12±0.5a	52.90±7.0a
Group II	Pre-T	35	19.0±7.2b	395.7±16.5b	2.45±0.8b	43.02±6.8b
	Post-T	35	15.62±7.9	355.6±9.5	1.80±0.7	46.54±6.9

αPre-T: before treatment; Post-T: after treatment;

^aP＜0.05 vs before treatment in the same group;

^bP<0.01 vs group III.